Intravenous Human Immunoglobulin for the Treatment of Immune-Mediated Hemolytic Anemia in 13 Dogs
article
OA: bronze
CC0
⤵ 1 in-corpus citation
AI-generated summary
Intravenous immunoglobulin, given to 13 dogs with immune-mediated hemolytic anemia unresponsive to prednisone, increased packed cell volume in 11 dogs with minimal adverse effects.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
Intravenous immunoglobulin (IVGG) was administered to 13 of 37 dogs with immune-mediated hemolytic anemia. All dogs received concurrent prednisone therapy, 14 dogs also received cyclophosphamide; and a single dog each received cyclosporine, azathioprine, and danazol. Dogs that responded to prednisone therapy without IVGG generally did so within 7 days (mean +/- standard deviation = 5.6 +/- 2.9 days). Intravenous immunoglobulin was administered after 10.4 +/- 6.6 days of prednisone therapy as an intravenous infusion of 0.5 g/kg (range 0.25 to 0.73 g/kg). Eleven dogs received a single treatment, 2 dogs each received 2 treatments. No relevant adverse effects were noted. Eleven dogs had an increase in PCV of at least 4% 2.2 +/- 1.5 days after IVGG infusion. In 10 of these dogs, the PCV continued to increase until the time of hospital discharge. One responder died 1 hour after the increase in PCV, 1 dog was euthanized within 24 hours of IVGG administration, and 1 dog had no response over a period of 13 days. Results of this study suggest that IVGG therapy may be of value in dogs with immune-mediated hemolytic anemia that do not respond within 7 days of appropriate corticosteroid therapy.
My notes (saved in your browser only)
Citation neighborhood (no data yet)
We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.
References (22)
- doi:10.2460/javma.1993.202.05.783 via openalex
- doi:10.2460/javma.1989.195.02.246 via openalex
- doi:10.2165/00002018-199309040-00003 via openalex
- doi:10.1016/s0140-6736(94)92205-5 via openalex
- doi:10.1172/jci114387 via openalex
- doi:10.7326/0003-4819-112-4-278 via openalex
- doi:10.2460/javma.1995.206.12.1895 via openalex
- doi:10.1111/j.1751-0813.1985.tb07257.x via openalex
- doi:10.1056/nejm199201093260206 via openalex
- doi:10.1002/ajh.2830440404 via openalex
- W59807547 via openalex
- W179680484 via openalex
- W2401710950 via openalex
- W2462925590 via openalex
- W2993759000 via openalex
- W4290129987 via openalex
- doi:10.1182/blood.v77.2.376.376 via openalex
- doi:10.1007/bf01533367 via openalex
- doi:10.1201/9781482283723-38 via openalex
- doi:10.1007/bf00918683 via openalex
- doi:10.1007/bf00920238 via openalex
- doi:10.1002/1097-0142(19910915)68:6+<1430::aid-cncr2820681405>3.0.co;2-4 via openalex
Source provenance
- openalex
- last seen: 2026-05-14T06:20:47.804276+00:00
License: CC0
· commercial use OK